Research
Print page Print page
Switch language
Hvidovre Hospital - a part of Copenhagen University Hospital
Published

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. All-cause Mortality Due to Bacteremia during a 60-Day Non-Physician Healthcare Worker Strike

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hepatic steatosis associated with exposure to elvitegravir and raltegravir

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Oral and anal carriage of Streptococcus pneumoniae among sexually active men with HIV who have sex with men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.

METHODS: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).

RESULTS: The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38-.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29-.46).

CONCLUSIONS: Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.

Original languageEnglish
Article numberciab536
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume73
Issue number11
Pages (from-to)2031-2036
Number of pages6
ISSN1058-4838
DOIs
Publication statusPublished - 1 Dec 2021

    Research areas

  • Adenosine Monophosphate/analogs & derivatives, Alanine/analogs & derivatives, Antiviral Agents/therapeutic use, COVID-19/drug therapy, Cohort Studies, Dexamethasone/therapeutic use, Humans, Retrospective Studies, SARS-CoV-2, dexamethasone, survival, remdesivir, COVID-19, pneumonia

ID: 66133261